Junping Yang, MD
Endocrinology, Diabetes & Metabolism · Saint Joseph, MONPI 1831120773
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 62.3% of it on its own, with 49 other manufacturers making up the rest. Reporting peaked in 2019 at $21,069 and has fallen 84.9% since, to $3,192 in 2025. Among endocrinology, diabetes & metabolism clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 719 payments — averaging $63.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$28K
- Aegerion Pharmaceuticals, Inc.$3K
- Novo Nordisk$1K
- Mannkind Corporation$1K
- Amgen$1K
- Abbott$955
- plus $9K from 44 others
What the payments were for
- Consulting fees$2,6106%
- Speaking & faculty fees$27,00059%
- Travel & lodging$1,8354%
- Food & beverage$14,10631%
- Education$80%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$26,931
- MYALEPT$3,474
- AFREZZA$850
- CeQur Simplicity$693
- Minimed 530G$363
- MYCAPSSA$325
- MINIMED 780G$319
- RYBELSUS$232
- Korlym$113
- Wegovy$105
How this compares
$45,617 in reported general payments places this provider in the 90th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 370 | $466,798 |
| FarxigaDapagliflozin Propanediol | 256 | $309,097 |
| MounjaroTirzepatide | 202 | $241,032 |
| JardianceEmpagliflozin | 179 | $202,715 |
| JanuviaSitagliptin Phosphate | 208 | $184,055 |
| TrulicityDulaglutide | 119 | $137,309 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 88 | $129,843 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 451 | $104,213 |
| Tresiba Flextouch U-200Insulin Degludec | 103 | $91,121 |
| Tresiba Flextouch U-100Insulin Degludec | 86 | $81,121 |
| InvokanaCanagliflozin | 73 | $80,422 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 68 | $78,867 |
| RybelsusSemaglutide | 49 | $75,622 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 134 | $65,834 |
| Humalog Kwikpen U-100Insulin Lispro | 149 | $64,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,394 | $549,434439 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $825 | $391,648361 claims |
| AstraZenecaFarxiga | $28,433 | $309,097256 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $699 | $278,438255 claims |
| MerckJanuvia, Janumet, Janumet Xr | $206 | $236,900255 claims |
| Johnson & JohnsonInvokana | $70 | $80,42273 claims |
| AbbVieSynthroid | $131 | $14,435157 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $55 | $10,7801,217 claims |
| Sanofi-aventis U.S. LLCLantus | $492 | $6,82431 claims |
| PfizerPremarin | $90 | $5,44416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Joseph
- Ahmad Al-MubaslatSaint Joseph$35K
- Sherry ZhouSaint Joseph$16K
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.